A firefighter's hand resting beside a tirzepatide vial and carton on a bathroom counter in morning light

    Rx required

    Tirzepatide

    Weekly weight-loss treatment with straightforward pricing and real clinical support.

    $349 for 3 months

    $116.33/month equivalent

    You pay $0 if you aren't approved.

    Pricing

    1 Month

    $169 today

    $229 each month after

    3 Months

    Best value

    $349 today

    $349 every 3 months

    $116.33/month equivalent

    Medication, supplies, shipping and care-team messaging included.

    See if you qualify

    No membership fee. No hidden add-ons. Billing, refills and cancellation policy

    Off-duty first responder lacing running shoes on a truck tailgate at dawn

    Built for people who work nights and still want their body to respond.

    How it works

    1. Off-duty first responder sitting in a gym, completing a health intake form on his phone

      1. Online intake

      A private health questionnaire from your phone, about five minutes.

    2. A hand holding a phone on a video visit with a clinician in navy scrubs

      2. Clinical review

      A clinician licensed in your state decides whether treatment fits.

    3. Open RespondWell shipping box with a cold-packed medication vial, injection instructions, syringes and alcohol prep pads

      3. Delivered to your door

      Medication and supplies arrive cold-packed with shipping included.

    RespondWell compounded tirzepatide GLP-1 + GIP vial on a kitchen countertop

    What tirzepatide can do:

    A once-weekly injection that acts on the GLP-1 and GIP receptors, slowing gastric emptying and quieting appetite signals so fullness lasts longer after a meal.

    In a 72-week trial of 2,539 adults, the highest studied dose produced a 20.9% mean reduction in body weight alongside lifestyle counseling.¹

    This trial studied FDA-approved tirzepatide products. It was not conducted on the compounded formulation dispensed here, and results in a trial population do not predict an individual outcome. Individual results vary and are not guaranteed.

    Frequently Asked Questions

    Tirzepatide is typically suitable for adults seeking substantial weight loss, especially if your BMI is over 27 with weight-related conditions or over 30. It's not recommended for people with a history of medullary thyroid cancer, pancreatitis or severe gastrointestinal disease.

    Clinical trials show weight-loss of up to 20.9% over 72 weeks. Most users notice reduced appetite and cravings within the first few weeks, with steady weight loss thereafter. It's important to note that compounded medications should not be presumed equivalent to their branded counterparts, and they are not reviewed by the FDA for safety or effectiveness.

    Tirzepatide is a dual agonist that targets both GLP-1 and GIP receptors, while semaglutide only targets GLP-1. This dual action often yields greater weight-loss results.

    The most common side effects are GI-related – nausea, constipation, diarrhea, vomiting, and stomach discomfort – and they often improve over time. We start low and increase doses gradually to help minimize side effects. Rare but serious risks have been reported, including pancreatitis, gallbladder problems, and kidney injury. Tell your care team before surgery/anesthesia, since GLP-1s can slow gastric emptying. Animal studies indicated a risk of thyroid C-cell tumors. The correlation to humans has not been established, but you should avoid GLP-1 medications if you or your family has a history of MTC or MEN2. Review Important Safety Information for full details.

    Most patients find them virtually painless. Our medications are administered subcutaneously (under the skin) — not intramuscularly — using the small insulin syringes our pharmacies send you. At 29–32 gauge, these needles are way finer and shorter than the 22–24 gauge needles you're accustomed to for things like flu shots. (Higher gauge = thinner needle.)

    Safety information

    Boxed warning: thyroid C-cell tumors

    • · Tirzepatide caused thyroid C-cell tumors in rodents. It is unknown whether it causes medullary thyroid carcinoma (MTC) in humans.
    • · Do not use if you or a family member has had MTC, or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
    • · Tell your provider immediately about a neck lump or swelling, hoarseness, trouble swallowing, or shortness of breath.

    Tirzepatide isn't an option if any of these apply

    • · You or a family member has had medullary thyroid carcinoma, or you have MEN 2
    • · You are pregnant, trying to conceive, or breastfeeding
    • · You have a history of pancreatitis, gastroparesis, or active gallbladder disease
    • · You take another GLP-1 medication or have had a reaction to one

    Safety details

    Common gastrointestinal effects

    • · Nausea, vomiting, diarrhea, constipation, abdominal pain, indigestion

    Serious risks to discuss with your provider

    • · Pancreatitis: severe, persistent abdominal pain, with or without vomiting

    Before you start, tell your provider

    • · If you are pregnant, planning pregnancy, or breastfeeding — tirzepatide is not for use in pregnancy

    Compounded tirzepatide with glycine, prepared by a licensed US compounding pharmacy. Compounded medications are not FDA-approved and are not evaluated by the FDA for safety, effectiveness, or quality. Glycine is a formulation excipient — it is not included to improve weight loss or tolerability.

    This page is a summary. It does not replace counseling from your clinician or the official prescribing information for tirzepatide. Call 911 for emergencies.

    Related Reading

    More on Tirzepatide

    Deeper dives from our editorial team — pricing, dosing, and the research behind it.

    About Our Medications

    Our treatments contain active pharmaceutical ingredients that conform to USP (United States Pharmacopeia) monograph standards and are custom-compounded by licensed 503A and 503B pharmacies to meet your individual needs. Compounded medications are not FDA-approved finished drug products. The suggested formulations are provided for reference only and are based on formulations that have historically been prescribed by duly licensed prescribers. All medications are prepared in accordance with a valid prescription from a licensed healthcare provider following a medical consultation.

    Medical Consultation Required

    Our licensed medical providers will evaluate your health history and goals to determine the most appropriate treatment option for you. Prescriptions are subject to medical evaluation and are not guaranteed. If we are unable to prescribe treatment after your consultation, you pay zero. Independent clinical services provided by: Wasef Health, PC c/o Michael Wasef MD. Licensed in all 50 states + DC.

    Clinical References

    1. 1Jastreboff AM, et al. SURMOUNT-1: Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.
    2. 2Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). Lancet. 2021;398(10313):1811-1824.
    3. 3Malhotra A, Grunstein RR, Gao L, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391(13):1193-1205.